Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2025-11-15 Regulatory Filings
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the recording of an earnings call for the second quarter and half year ended September 30, 2025. It references the unaudited financial results and provides a link to the audio recording of the earnings call. The document does not contain the actual financial results or detailed financial data but is an announcement about the earnings call recording. The document length is 2210 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, it fits best under the category of Call Transcript (CT) since it relates to the earnings call, but since it only announces the recording and does not provide the transcript text itself, it is more appropriate to classify it as a Regulatory Filing (RNS) as a general regulatory announcement about the earnings call recording availability.
2025-11-15 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated November 14, 2025, announcing the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes extracts of financial results published in newspapers and uploaded on the company's website. The document contains actual financial data such as revenue, net profit/loss, earnings per share, and notes on the financial results. It is not merely an announcement of a report publication but includes substantive financial information for a quarterly period. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2026
2025-11-14 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation for the Second Quarter and half year ended September 30, 2025' and is addressed to stock exchanges, indicating it is a formal communication of financial results. It contains detailed financial highlights, segment-wise revenue splits, geographic revenue splits, management commentary, and regulatory updates. The content includes forward-looking statements, financial metrics like EBITDA, PAT, revenue, margins, and operational updates. The document is about 15,000 characters long, which is substantial and contains detailed financial and operational data. It is explicitly called an 'Investor Presentation' in the text and the subject line. Therefore, this document fits the category of an Investor Presentation (IP).
2025-11-13 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Concord Biotech Limited dated November 13, 2025, reporting the outcome of a Board Meeting where the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025, were approved. It includes the unaudited financial results, a limited review report by the statutory auditors, and detailed financial statements such as the statement of assets and liabilities and cash flow statement. The presence of comprehensive financial data for a period shorter than a full fiscal year (quarter and half year), along with the auditor's limited review report, indicates this is an Interim / Quarterly Report. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2026
2025-11-13 English
Integrated Filing- Financial
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from Concord Biotech Limited dated November 13, 2025, reporting the outcome of a Board Meeting where unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025, were approved. It includes financial tables with income, expenses, assets, liabilities, and cash flow statements. The document also contains a Limited Review Report by the statutory auditors (B S R & Co. LLP) on these unaudited financial results, referencing Indian Accounting Standard 34 for interim financial reporting. The presence of comprehensive financial data for a period shorter than a full fiscal year, along with auditor review, indicates this is an Interim / Quarterly Report. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2026
2025-11-13 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Concord Biotech Limited dated November 13, 2025, reporting the outcome of a Board Meeting where unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025, were approved. It includes a Limited Review Report by the statutory auditors (B S R & Co. LLP) with an unmodified opinion, which is typical for interim financial results. The document contains extensive financial data such as income statements, balance sheets, and cash flow statements for the period ending September 30, 2025. The presence of unaudited quarterly and half-year financial results, along with the auditor's limited review report, aligns with the characteristics of an Interim / Quarterly Report (IR). The document is not merely an announcement or a certification but contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2026
2025-11-13 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.